The story of talcum powder and ovarian cancer spans 55 years, from the first discovery of talc particles in ovarian tumors to billion-dollar jury verdicts. It is a story of scientific findings that were published and then ignored, internal corporate memos that acknowledged risk and recommended silence, and a legal reckoning that is still unfolding.
This timeline tracks three parallel threads: the scientific research, Johnson & Johnson’s corporate knowledge and actions, and the legal proceedings that followed.
1970s: The First Discoveries
1971
Science: Welsh doctors W.J. Henderson, T.C. Joslin, and others publish the first study documenting talc particles “deeply embedded” in ovarian and cervical tumor tissue. This is the earliest evidence that talc applied externally can migrate to the ovaries.
Industry: Johnson & Johnson’s Baby Powder is already one of the best-selling personal care products in the United States. The company has marketed talcum powder for feminine hygiene use for decades.
1978
Science: Dr. Daniel W. Cramer at Harvard Medical School publishes research linking perineal talc use to ovarian cancer. Cramer would go on to become one of the most prominent researchers in this field, consistently finding associations between genital talc use and ovarian cancer in subsequent studies over the next four decades.
1980s: Evidence Mounts, Marketing Expands
1982
Science: A study published in the journal Cancer reports that women who dust their genitals or sanitary napkins with talcum powder face approximately three times the risk of developing ovarian cancer compared to non-users. This is among the first studies to quantify the risk elevation.
Industry: J&J launches aggressive television advertising for Shower to Shower body powder with the jingle “Just a sprinkle a day helps keep odor away,” specifically encouraging application to intimate areas.
1990s: Internal Warnings, Continued Sales
1992
Science: Research confirms a three-fold increased risk of ovarian cancer from extended genital powder use, building on the 1982 findings with larger study populations.
Industry: J&J internal marketing documents reveal strategies to target African American and Hispanic women for talcum powder sales. These communities would later be shown to have higher rates of genital talc use and, consequently, higher ovarian cancer risk.
1993
Regulatory: The U.S. National Toxicology Program classifies talc as a carcinogen, adding scientific weight to the growing body of evidence.
1994
Advocacy: The Cancer Prevention Coalition formally demands that J&J place warning labels on talcum powder products about the potential ovarian cancer risk. J&J refuses.
1997
Industry: An internal J&J memo warns of the ovarian cancer danger from talcum powder. This memo would remain hidden from the public for decades, eventually surfacing during litigation discovery and becoming a key piece of evidence in trials.
The 1997 internal memo is significant because it demonstrates that J&J’s own personnel acknowledged the cancer risk, undermining the company’s defense that the science was uncertain or inconclusive.
2000s: Broader Recognition
2003
Science: Meta-analyses combining data from multiple studies consistently show a 20 to 30% increased risk of ovarian cancer with genital talc use. The consistency across different research groups and study designs strengthens the case for causation.
2006
Regulatory: IARC classifies perineal talc use as “possibly carcinogenic to humans” (Group 2B). This is the first time an international health authority formally recognizes the potential cancer risk, though the “possibly” classification reflects limited evidence at the time.
2010s: From Courtroom to Crisis
2010
Science: A WHO review synthesizing eight studies identifies a 30 to 60% increased ovarian cancer risk among women who used talc-based body powder. The range reflects variation across studies, but the direction is consistently upward.
2013
Legal: The first plaintiff victory in a talcum powder ovarian cancer lawsuit. Deane Berg of South Dakota proves that J&J’s product warnings were inadequate. The jury finds in her favor but does not award damages. Despite the zero-dollar outcome, the case establishes that talc-ovarian cancer claims can survive a jury trial.
Science: A pooled analysis of eight case-control studies documents a 20 to 30% increased risk of ovarian cancer with genital talcum powder use, consistent with earlier meta-analyses.
2016
Legal: The floodgates open. A St. Louis jury awards $72 million to the estate of Jacqueline Fox, who used J&J Baby Powder for 35 years before dying of ovarian cancer. This is the first major talc verdict and triggers thousands of new lawsuit filings.
In May, Gloria Ristesund receives a $55 million verdict in St. Louis.
Science: A study focused on African American women finds a 40 to 44% increased ovarian cancer risk from talcum powder use. The African American Cancer Epidemiology Study (AACES) reports that 63% of women with ovarian cancer had used talc, compared to 53% of healthy controls.
2017
Legal: Three major verdicts in a single year. Deborah Giannecchini receives $70 million (March, St. Louis). Lois Slemp receives $110 million (May, St. Louis). Eva Echeverria receives $417 million (August, Los Angeles). The escalating awards reflect growing evidence and jury anger at J&J’s conduct.
2018
Legal: The landmark $4.69 billion verdict. A St. Louis jury awards 22 women and their families the largest talcum powder verdict in history, finding that J&J acted with actual malice. (Later reduced to $2.12 billion on appeal, but upheld by the U.S. Supreme Court.)
2020s: Reckoning and Resistance
2020
Science: The NIH Sister Study publishes findings in the Journal of Clinical Oncology confirming that women who regularly used talc in the genital area had statistically significant increased ovarian cancer risk, with the strongest associations in frequent, long-term users.
Industry: J&J discontinues talc-based Baby Powder in the United States and Canada, replacing it with a cornstarch formula. The company continues selling the talc version internationally.
Legal: A New Jersey jury awards $750 million in a talc-related mesothelioma case.
2021
Industry/Legal: J&J executes the first “Texas Two-Step,” creating LTL Management LLC to absorb talc liabilities and filing for Chapter 11 bankruptcy. The filing triggers an automatic stay, halting approximately 38,000 lawsuits. People with cancer are forced to wait.
2023
Legal: The Third Circuit Court of Appeals dismisses the LTL Management bankruptcy, ruling it was filed in bad faith and constituted an abuse of the bankruptcy system. Lawsuits resume. J&J immediately files a second LTL bankruptcy.
Industry: J&J discontinues talc-based Baby Powder worldwide.
2024
Regulatory: IARC upgrades talc to Group 2A (“probably carcinogenic to humans”), the most significant regulatory action on talc to date. The decision is based on limited but consistent human evidence, sufficient animal evidence, and strong mechanistic evidence.
Science: NIH follow-up analysis of 50,000+ women reinforces the association between frequent genital talc use and ovarian cancer, particularly during reproductive years.
Legal: The Third Circuit rejects the second LTL Management bankruptcy. J&J proposes an $8.9 billion settlement. A $700 million settlement resolves claims from 42 states but does not address the bulk of ovarian cancer cases.
2025
Legal: Three major developments:
- J&J’s third bankruptcy attempt (Red River Talc LLC) is rejected in March
- $966 million verdict for Mae Moore’s estate in Los Angeles (October)
- $1.5 billion verdict for Cherie Craft in Baltimore (December), the largest individual talc award in history
- $40 million verdict for two women with ovarian cancer in California (December)
- Approximately 3,000 talcum powder lawsuits filed in the United Kingdom (October)
- Pennsylvania establishes a new state MDL for talc ovarian cancer cases (June)
2026
Legal: The litigation continues to produce verdicts:
- $250,000 verdict for deceased woman’s estate in Pennsylvania (February)
- $42 million mesothelioma verdict in Massachusetts
- $24 million default judgment against Gold Bond maker (California)
- Pennsylvania state MDL trial begins (January)
- Total pending lawsuits exceed 90,000
Where Things Stand
Fifty-five years after the first scientific discovery, the talc-ovarian cancer saga is approaching a resolution, though slowly. The science is stronger than ever (IARC Group 2A classification). The legal precedent is firmly established (billions in verdicts upheld). And J&J’s three attempts to avoid full accountability through bankruptcy have all been rejected.
What remains unresolved: a comprehensive settlement that provides meaningful compensation to the tens of thousands of women and families who filed claims. With trials scheduled throughout 2026 and no bankruptcy stay in place, the path forward is through the courts.
When did scientists first discover the talc-ovarian cancer link?▼
In 1971, Welsh doctors published the first study finding talc particles embedded in ovarian and cervical tumor tissue. In 1978, Dr. Daniel Cramer at Harvard published research specifically linking perineal talc use to ovarian cancer. By 1982, studies were quantifying the risk at approximately three times normal for genital talc users.
When did Johnson and Johnson know about the cancer risk?▼
Internal documents discovered during litigation show that J&J was aware of the ovarian cancer risk by at least the 1990s. A 1997 internal memo specifically warned of the danger. The Cancer Prevention Coalition demanded warning labels in 1994, which J&J refused. Earlier documents suggest awareness dating to the 1970s, when the first scientific studies were published.
When did J&J stop selling talc-based Baby Powder?▼
J&J discontinued talc-based Baby Powder in the United States and Canada in 2020, replacing it with a cornstarch formula. The company continued selling the talc version internationally until 2023, when it discontinued global talc-based Baby Powder production.
References
The Lancet. (1971). Talc Particles in Ovarian and Cervical Tumours.
https://pubmed.ncbi.nlm.nih.gov/4105952/
Obstetrics & Gynecology / Dr. Daniel Cramer. (1982). Perineal Talc Exposure and Ovarian Cancer Risk.
https://pubmed.ncbi.nlm.nih.gov/25003394/
International Agency for Research on Cancer / WHO. (2024-07-05). IARC Classifies Talc as Probably Carcinogenic to Humans.
https://monographs.iarc.who.int/news-events/iarc-classifies-talc-as-probably-carcinogenic-to-humans/
NPR. (2018-07-13). Jury Awards $4.7 Billion To Women In Johnson & Johnson Talcum Powder Suit.
https://www.npr.org/2018/07/13/628684038/jury-awards-4-7-billion-to-women-in-johnson-johnson-talcum-powder-suit
Third Circuit Court of Appeals. (2023-01). Third Circuit Dismisses LTL Management Bankruptcy.
https://www.ca3.uscourts.gov/
Reuters. (2020-05-19). J&J Discontinues Talc-Based Baby Powder.
https://www.reuters.com/
Cancer Epidemiology, Biomarkers & Prevention. (2016-09). African American Cancer Epidemiology Study: Talc and Ovarian Cancer.
https://pubmed.ncbi.nlm.nih.gov/27197289/